KFAS
SMMT icon

Keating Financial Advisory Services’s Summit Therapeutics SMMT Stock Holding History

Keating Financial Advisory Services’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146 Buy
10
+8
+400% +$142 ﹤0.01% 2451
2026
Q1 		$38 Buy
2
+1
+100% +$16 ﹤0.01% 2472
2025
Q4 		$17 Buy
+1
New +$19 ﹤0.01% 2200

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Keating Financial Advisory Services's SMMT Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Summit Therapeutics (SMMT) stake by 400% in Q2 2026, buying an estimated $142 and bringing the position to 10 shares worth $146. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

Keating Financial Advisory Services first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Keating Financial Advisory Services held 10 shares of Summit Therapeutics worth $146 as of Q2 2026.
  • Keating Financial Advisory Services bought 8 Summit Therapeutics shares in Q2 2026, an estimated $142.
  • Summit Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2451 holding.
  • Keating Financial Advisory Services first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.